Squarepoint’s United Therapeutics UTHR Stock Holding History

Squarepoint’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.3M	Sell	2,400 -7,000	-74%	-$3.94M	﹤0.01%	2698
2026 Q1	$5.57M	Buy	+9,400	New	+$4.68M	0.01%	1416
2025 Q4	–	Sell	-600	Closed	-$252K	–	4930
2025 Q3	$252K	Buy	+600	New	+$202K	﹤0.01%	3798
2024 Q4	–	Sell	-2,200	Closed	-$788K	–	5529
2024 Q3	$788K	Sell	2,200 -7,500	-77%	-$2.53M	﹤0.01%	2783
2024 Q2	$3.09M	Buy	9,700 +3,800	+64%	+$1.01M	0.01%	1719
2024 Q1	$1.36M	Buy	+5,900	New	+$1.33M	﹤0.01%	2358

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Squarepoint's UTHR Position: Q2 2026 in Review

Squarepoint opened a new position in United Therapeutics (UTHR) in Q2 2026: 48,656 shares worth $26.4M. The stake represents 0.03% of the portfolio and ranks #573 among its holdings. This is a return to the name: Squarepoint previously reported a position in UTHR as recently as Q3 2025.

Squarepoint first reported a position in UTHR in Q4 2015 and has held it in 33 quarters since. The position peaked at $40.8M in Q1 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Squarepoint held 48,656 shares of United Therapeutics worth $26.4M as of Q2 2026.
United Therapeutics was a new Squarepoint position in Q2 2026.
United Therapeutics made up 0.03% of Squarepoint's portfolio in Q2 2026, its #573 holding.
Squarepoint first reported a position in United Therapeutics in Q4 2015 and has held it in 33 quarters since.
Squarepoint's United Therapeutics position peaked at $40.8M in Q1 2024.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.